Indications: Ponaxen is prescribed for:

• Chronic myeloid leukemia (CML) in patients who didn’t respond well to previous tyrosine kinase inhibitor (TKI) therapy or couldn’t tolerate it.
• Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in patients who didn’t respond well to prior TKI therapy or couldn’t tolerate it.

Pharmacology: Ponaxen (Ponatinib) is a tyrosine kinase inhibitor (TKI) that targets several tyrosine kinases, including BCR-ABL, the abnormal kinase responsible for CML and Ph+ ALL. It curbs cell growth and triggers cell death in BCR-ABL-expressing cells, even those with mutations resistant to other TKIs.

Dosage and Administration: The standard Ponaxen dose is 45 mg once daily, orally, with or without food. Adjustments might be necessary based on individual patient response and tolerance.

Interactions: Ponaxen can interact with other drugs, emphasizing the importance of informing healthcare providers about all medications, including prescriptions, over-the-counter drugs, vitamins, and herbal supplements.

Side Effects: Common side effects of Ponaxen may involve arterial blood clotting, high blood pressure, liver issues, pancreatitis, bone marrow suppression, and fluid retention. Severe effects might encompass heart failure, arterial blockages, and liver problems.

Precautions and Warnings: Ponaxen might heighten the risk of arterial blood clots like heart attacks and strokes, warranting careful patient monitoring. It may also prompt liver issues, pancreatitis, and fluid retention, mandating regular liver and pancreatic enzyme tests.

Overdose Effects: In instances of overdose, supportive care is crucial. Specific antidotes for Ponaxen overdose aren’t available, so treatment revolves around alleviating symptoms and providing support.